vs
Side-by-side financial comparison of PAMT CORP (PAMT) and Stoke Therapeutics, Inc. (STOK). Click either name above to swap in a different company.
Stoke Therapeutics, Inc. is the larger business by last-quarter revenue ($158.6M vs $141.3M, roughly 1.1× PAMT CORP). Stoke Therapeutics, Inc. runs the higher net margin — 71.2% vs -20.7%, a 91.9% gap on every dollar of revenue. On growth, Stoke Therapeutics, Inc. posted the faster year-over-year revenue change (3661.1% vs -15.1%). Stoke Therapeutics, Inc. produced more free cash flow last quarter ($131.7M vs $-25.0M).
Stoke Therapeutics, Inc. is a clinical-stage biotechnology company developing innovative RNA-targeted therapies for severe rare genetic diseases. Its lead candidates address unmet needs for Dravet syndrome, a rare epilepsy, and other neurological monogenic disorders, serving patients across North America and global markets.
PAMT vs STOK — Head-to-Head
Income Statement — Q4 FY2025 vs Q1 FY2025
| Metric | | |
|---|---|---|
| Revenue | $141.3M | $158.6M |
| Net Profit | $-29.3M | $112.9M |
| Gross Margin | — | — |
| Operating Margin | -27.0% | 70.2% |
| Net Margin | -20.7% | 71.2% |
| Revenue YoY | -15.1% | 3661.1% |
| Net Profit YoY | 7.4% | 528.0% |
| EPS (diluted) | $-1.38 | $1.90 |
Green = leading value per metric. Periods may differ when fiscal calendars don't align.
8-Quarter Revenue & Profit Trend
Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.
| Q4 25 | $141.3M | — | ||
| Q3 25 | $150.3M | — | ||
| Q2 25 | $151.1M | — | ||
| Q1 25 | $155.3M | $158.6M | ||
| Q4 24 | $166.5M | $22.6M | ||
| Q3 24 | $182.6M | — | ||
| Q2 24 | $182.9M | — | ||
| Q1 24 | $182.6M | — |
| Q4 25 | $-29.3M | — | ||
| Q3 25 | $-5.6M | — | ||
| Q2 25 | $-9.6M | — | ||
| Q1 25 | $-8.1M | $112.9M | ||
| Q4 24 | $-31.6M | $-10.5M | ||
| Q3 24 | $2.4M | — | ||
| Q2 24 | $-2.9M | — | ||
| Q1 24 | $281.0K | — |
| Q4 25 | -27.0% | — | ||
| Q3 25 | -3.8% | — | ||
| Q2 25 | -7.3% | — | ||
| Q1 25 | -5.9% | 70.2% | ||
| Q4 24 | -22.6% | -60.4% | ||
| Q3 24 | 1.3% | — | ||
| Q2 24 | -0.4% | — | ||
| Q1 24 | -0.4% | — |
| Q4 25 | -20.7% | — | ||
| Q3 25 | -3.7% | — | ||
| Q2 25 | -6.4% | — | ||
| Q1 25 | -5.2% | 71.2% | ||
| Q4 24 | -19.0% | -46.4% | ||
| Q3 24 | 1.3% | — | ||
| Q2 24 | -1.6% | — | ||
| Q1 24 | 0.2% | — |
| Q4 25 | $-1.38 | — | ||
| Q3 25 | $-0.27 | — | ||
| Q2 25 | $-0.46 | — | ||
| Q1 25 | $-0.37 | $1.90 | ||
| Q4 24 | $-1.44 | $-0.15 | ||
| Q3 24 | $0.11 | — | ||
| Q2 24 | $-0.13 | — | ||
| Q1 24 | $0.01 | — |
Balance Sheet & Financial Strength
Snapshot of each company's liquidity, leverage and book value from the latest quarter.
| Metric | | |
|---|---|---|
| Cash + ST InvestmentsLiquidity on hand | $83.7M | $274.8M |
| Total DebtLower is stronger | $333.9M | — |
| Stockholders' EquityBook value | $210.5M | $350.1M |
| Total Assets | $697.9M | $406.9M |
| Debt / EquityLower = less leverage | 1.59× | — |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | $83.7M | — | ||
| Q3 25 | $115.6M | — | ||
| Q2 25 | $117.3M | — | ||
| Q1 25 | $102.7M | $274.8M | ||
| Q4 24 | $110.7M | $128.0M | ||
| Q3 24 | $92.3M | — | ||
| Q2 24 | $114.0M | — | ||
| Q1 24 | $125.8M | — |
| Q4 25 | $333.9M | — | ||
| Q3 25 | — | — | ||
| Q2 25 | — | — | ||
| Q1 25 | — | — | ||
| Q4 24 | $325.6M | — | ||
| Q3 24 | — | — | ||
| Q2 24 | — | — | ||
| Q1 24 | — | — |
| Q4 25 | $210.5M | — | ||
| Q3 25 | $239.5M | — | ||
| Q2 25 | $244.9M | — | ||
| Q1 25 | $269.6M | $350.1M | ||
| Q4 24 | $277.5M | $229.0M | ||
| Q3 24 | $308.9M | — | ||
| Q2 24 | $306.7M | — | ||
| Q1 24 | $314.6M | — |
| Q4 25 | $697.9M | — | ||
| Q3 25 | $715.2M | — | ||
| Q2 25 | $707.9M | — | ||
| Q1 25 | $712.6M | $406.9M | ||
| Q4 24 | $741.7M | $271.6M | ||
| Q3 24 | $756.7M | — | ||
| Q2 24 | $733.5M | — | ||
| Q1 24 | $746.4M | — |
| Q4 25 | 1.59× | — | ||
| Q3 25 | — | — | ||
| Q2 25 | — | — | ||
| Q1 25 | — | — | ||
| Q4 24 | 1.17× | — | ||
| Q3 24 | — | — | ||
| Q2 24 | — | — | ||
| Q1 24 | — | — |
Cash Flow & Capital Efficiency
How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.
| Metric | | |
|---|---|---|
| Operating Cash FlowLast quarter | $-5.8M | $131.8M |
| Free Cash FlowOCF − Capex | $-25.0M | $131.7M |
| FCF MarginFCF / Revenue | -17.7% | 83.0% |
| Capex IntensityCapex / Revenue | 13.6% | 0.1% |
| Cash ConversionOCF / Net Profit | — | 1.17× |
| TTM Free Cash FlowTrailing 4 quarters | $-23.4M | — |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | $-5.8M | — | ||
| Q3 25 | $5.9M | — | ||
| Q2 25 | $12.2M | — | ||
| Q1 25 | $5.0M | $131.8M | ||
| Q4 24 | $15.2M | $-23.2M | ||
| Q3 24 | $15.5M | — | ||
| Q2 24 | $18.7M | — | ||
| Q1 24 | $9.6M | — |
| Q4 25 | $-25.0M | — | ||
| Q3 25 | $2.5M | — | ||
| Q2 25 | $5.9M | — | ||
| Q1 25 | $-6.8M | $131.7M | ||
| Q4 24 | $-39.9M | $-23.2M | ||
| Q3 24 | $-33.6M | — | ||
| Q2 24 | $4.1M | — | ||
| Q1 24 | $-12.2M | — |
| Q4 25 | -17.7% | — | ||
| Q3 25 | 1.7% | — | ||
| Q2 25 | 3.9% | — | ||
| Q1 25 | -4.4% | 83.0% | ||
| Q4 24 | -24.0% | -102.7% | ||
| Q3 24 | -18.4% | — | ||
| Q2 24 | 2.2% | — | ||
| Q1 24 | -6.7% | — |
| Q4 25 | 13.6% | — | ||
| Q3 25 | 2.3% | — | ||
| Q2 25 | 4.2% | — | ||
| Q1 25 | 7.6% | 0.1% | ||
| Q4 24 | 33.1% | 0.2% | ||
| Q3 24 | 26.9% | — | ||
| Q2 24 | 8.0% | — | ||
| Q1 24 | 12.0% | — |
| Q4 25 | — | — | ||
| Q3 25 | — | — | ||
| Q2 25 | — | — | ||
| Q1 25 | — | 1.17× | ||
| Q4 24 | — | — | ||
| Q3 24 | 6.44× | — | ||
| Q2 24 | — | — | ||
| Q1 24 | 34.11× | — |
Financial Flow Comparison
Revenue → gross profit → operating profit → net profit for each company.
Revenue Breakdown by Segment
PAMT
| Freight Transportation Service | $123.1M | 87% |
| Fuel Surcharge | $18.2M | 13% |
STOK
Segment breakdown not available.
